Hospital Infection Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2029
Hospital Infection Therapeutics Market: Overview
The report examines the past and current growth scenario in the global hospital infection therapeutics market to present an exhaustive analysis of growth trends and opportunities in the said market for the 2019 – 2029 forecast period. The report includes an elaborate executive summary, along with a market synopsis that covers information on key segments considered in the scope of this study.
Furthermore, the executive summary section covers market size, trends, and opportunities in key regions of the hospital infection therapeutics market. An in-depth qualitative and quantitative analysis of demand drivers, challenges, and competitive landscape is also covered in the executive summary section of hospital infection therapeutics market. Key companies operating in the hospital infection therapeutics market along with an overview of their growth strategies is covered in this section. The market overview section covers the regional outlook of the hospital infection therapeutics market. Market attractiveness analysis of key regions along with market size projections of key regions for the forecast period are covered in this section.
The report is compiled in a chapter-wise layout for reading comprehensibility. The report includes an array of graphs and tables for pictorial representation. The report is prepared using standard research methodologies, including Porter’s Five Forces analysis and SWOT analysis. A combination of primary and secondary research makes the report on the hospital infection therapeutics market a valuable tool. Analysts employed bottom-up approach for determining the market size using various indicators gathered from secondary sources, including population in 2017, variations in cost of therapeutics across major regions, prevalence of all types of hospital acquired infections in developed countries, and approval of therapeutics in specific regions. Top-down approach employed to obtain the market size for therapeutic segments, wherein revenues of all publicly listed companies were gathered through secondary sources. Moreover, historical year-on-year growth has been considered while estimating the market size. The market size forecast in terms of US$ Mn for each segment has been provided for the 2019 – 2029 forecast period, considering 2017 as the base year.
Hospital Infection Therapeutics Market: Key Segments
The hospital infection therapeutics market has been segmented based on infection, therapeutics, and region. By therapeutics, key segments into which the hospital infection therapeutics market is divided are anti-bacterial drugs, anti-viral drugs, anti-fungal drugs, and others. The anti-bacterial drugs segment is sub-segmented into protein synthesis inhibitors, cell wall synthesis inhibitors, and others. Key sub-segments within anti-fungal drugs segment are Amphotericin B, Caspofungin, and others. Based on infection, key segments into which the hospital infection therapeutics market is divided are urinary tract infections, hospital acquired pneumonia, bloodstream infections, gastrointestinal disorders, surgical site infections, and other hospital infections.
Hospital Infection Therapeutics Market: Regional Outlook
In terms of region, the hospital infection therapeutics market has been divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The report provides market size and growth rate projections for each of these segments for the 2018 -2026 forecast period. Furthermore, the report provides market size and growth rate projections for major countries in each region for the 2019 – 2029 forecast period.
Hospital Infection Therapeutics Market: Companies Mentioned
Key players operating in the hospital infection therapeutics market include Merck & Co. Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Bayer AG plc, Gilead sciences Inc., Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Sanofi S.A., and Basilea Pharmaceutica Ltd among others. Each of the companies is profiled for their business overview, product portfolio, financial standing, and SWOT analysis.
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report